Speaker / Panelist Biographies
Bonnie Anderson is the cofounder and CEO of Veracyte, a firm pioneering the emerging field of molecular cytology. Her career spans more than twenty-five years in regulated diagnostics and life science markets, where she has led both early-stage businesses and mature, global enterprises. Prior to Veracyte, Anderson provided strategic consulting services to venture capital firms and early-stage businesses following eighteen years in leadership positions at Beckman Coulter, including heading the company's global cellular analysis franchises in hematology and flow cytometry.
As Vice President of the intrapreneurial startup Immunomics Operations, Anderson successfully positioned the company's novel MHC tetramer technology as a vehicle for drug and vaccine developers to monitor ex-vivo immune response. She serves on the board of trustees of Keck Graduate Institute of Applied Life Sciences and on the advisory board for BayBio. She also has served on the boards of Thymed, GmbH, and Women in Biotechnology.
Greg Baxter has been a program director for the SBIR/STTR program at the National Science Foundation since September 2008. Prior to joining NSF, he was founder and CSO of Hurel Corporation, a biotechnology company developing cell-based microfluidic biochips for drug discovery and development applications. He is an adjunct associate professor with the Department of Biomedical Engineering at Cornell University. Prior to Hurel, Baxter was a senior scientist at the Cornell Nanoscale Science and Technology Facility, and the biotechnology liaison for the National Nanofabrication Users Network. Prior to Cornell, he held research positions at Molecular Devices Corporation. Baxter received his PhD in molecular biology and biochemistry from the University of California-Santa Barbara and did his postdoctoral research at Syntex Research.
Amy Belt, a director at Covidien Ventures, has fifteen years of venture capital, medical device operations, and health care provider consulting experience. Covidien is a venture capital group focused on investing in companies that develop innovative new medical devices, diagnostics, and pharmaceuticals. Prior to joining Covidien, Belt was a vice president with venture capital firm Advanced Technology Ventures, where she focused on investments in the medical device sector, working with new technologies spanning vascular, neurology, gastroenterology, gynecology, obesity, and diabetes.
Prior to ATV, Belt was at Guidant Corporation (later Abbott Vascular), where she led the international launch of several key products. Belt has launched and managed products in the United States, Europe, and Asia, working collaboratively across multiple functions and geographies. She began her career as a management consultant for APM/CSC Healthcare, where she optimized the clinical guidelines, operations, and strategy at approximately forty hospitals across the United States and Canada. Belt holds an MBA from the Walter Haas School of Business at the University of California-Berkeley and a BA in economics from Yale University. She is also a Kauffman Venture Fellow.
Steve Blank has had a thirty-three-year career as a successful businessman, conservationist, and teacher. As a Silicon Valley entrepreneur, Blank was part of or founded eight venture-backed companies, four of which went public.
After retiring, Blank moved from being an entrepreneur to teaching entrepreneurship at University of California-Berkeley, Stanford University, and the Columbia University/Berkeley Joint Executive MBA program. His teaching recognition includes the Earl F. Cheit Outstanding Teaching Award at University of California-Berkeley Haas School of Business and the Stanford University Undergraduate Teaching Award in the department of Management Science and Engineering.
In 2007, Governor Arnold Schwarzenegger appointed Blank to serve on the California Coastal Commission, the public body that regulates land use and public access on the California coast. Blank sits on Audubon California board and spent several years on the Audubon National board. He is also a board member of Peninsula Open Space Land Trust and, in 2009, became a trustee of University of California-Santa Cruz and the California League of Conservation Voters. Blank is the author of The Four Steps to the Epiphany, a book about building early-stage companies.
Zen Chu is a biomedical engineer and health care entrepreneur working across information technology, whole genome sequencing, medical devices, biomaterials implants, surgical tools, drug delivery, and regenerative medicine. He runs Accelerated Medical Ventures, serving as co-founder and investor for a few early-stage medical and software companies. As Entrepreneur-In-Residence at MIT, Chu mentors the Hacking Medicine program, channeling efforts to accelerate MIT’s health care ventures. He co-founded and served as founding CEO for 3D-Matrix Medical Inc., a venture-backed MIT regenerative medicine startup with worldwide partnerships and multiple human clinical trials in process, and an IPO in 2011. Chu also has worked for Harvard Medical School, NetVentures, and Hewlett-Packard, where he founded HPGarage, a new ventures group, in Silicon Valley. He earned an MBA from Yale and a BS in biomedical/electrical engineering from Southern Methodist University.
As Associate Director of the California Institute for Quantitative Biosciences (QB3), Douglas Crawford's goal is to help stimulate economic growth in California by promoting cross-discipline academic research and accelerating the transfer of the resulting innovations to the market. Crawford created and manages the first incubator within the University of California, the QB3 Garage@UCSF, which now has expanded to include the QB3 Garage@Berkeley, the QB3 Mission Bay Innovation Center, and the QB3 East Bay Innovation Center.
Crawford is also a founder and managing director of Mission Bay Capital, an $11.3 million seed-stage venture fund that seeks to make pivotal early-stage investments in bioscience companies emerging from the University of California. He is a board member of Redwood Biosciences (observer), Delpor, and the BayBio Institute. Crawford received his Ph.D. in biochemistry from University of California-San Francisco.
Nick Franano is founder and CEO of Novita Therapeutics, a privately held medical device and biopharmaceutical company developing novel treatments for cardiovascular, renal, and gastrointestinal diseases.
Franano previously founded Proteon Therapeutics, where he served as CEO and then Chief Scientific Officer, and is currently a board member. Franano invented Proteon’s vasodilation technology and methods for manufacturing and delivering the company’s lead drug candidate, PRT-201. He holds several patents and has numerous patents pending for related proteins, devices, and methods.
Franano led development of Proteon’s business plan and formulated the initial PRT-201 pre-clinical and clinical development plans. He also built the company’s R&D capability and manufacturing platform, managed its research efforts and intellectual property portfolio, and helped raise $84 million of financing. He also helped secure an agreement granting Novartis the option to acquire Proteon for at least $550 million in upfront and milestone payments after a Phase 2 PRT-201clinical trial. Franano received his master’s degree in biomedical research and Doctor of Medicine from Washington University, St. Louis. In 2009, Franano was named an Ernst & Young Entrepreneur of the Year for the Central Midwest.
Jason Greenberg, assistant professor of management at New York University Stern School of Business, researches economic and organizational sociology, social networks, and entrepreneurship. His dissertation work investigates how social networks affect the structure, functioning, and performance of entrepreneurial founding teams. This work has received awards from the Kauffman Foundation, the Institute for Operations Research and the Management Sciences, the Academy of Management, and the National Federation of Independent Business.
Prior to joining NYU Stern, Greenberg was a research fellow at the Institute for Quantitative Social Science at Harvard University and a research fellow at the Departments of Computer Science and Political Science at Northeastern University. He also has worked as a specialist clerk on the floor of the American Stock Exchange and as a management consultant specializing in organization and employee research for global and local companies.
Greenberg has advised several startups on organizational, strategic, and human capital issues, and helped found and manage several family-owned businesses. He received his B.A. from S.U.N.Y. Binghamton, his M.A. from the University of Florida, his M.P.P. from the University of Chicago, and his Ph.D. in Management from the Massachusetts Institute of Technology.
Karl Handelsman is fully immersed in his passion for science and innovation. This is clear, because the Managing Director of CMEA Capital’s Life Sciences division lists solar astronomy and synthetic biology as his favorite pastimes. An eleven-year CMEA veteran, Handelsman has worked alongside talented entrepreneurs through CMEA’s investments in Ambrx, Ensemble Discovery, Ilypsa, Intellikine, Kalypsys, Maxygen, Phenomix, Rigel, Syrrx, Tetraphase, and Xenoport. Prior to joining CMEA, Handelsman worked in biotech business development at Millennium. He was one of the first employees of Tularik a drug discovery company, where his business development role spanned corporate partnering, technology licensing, and operations. He also was among the first employees of Whitehead Institute, a premier research organization within Massachusetts Institute of Technology. Handelsman holds graduate degrees from MIT and Harvard Medical School.
Jennifer Hill is an eloquent (in Spanish too!) advocate for all things entrepreneurial. An international venture attorney, she advises technology and digital media companies and investors as they start, finance, and scale their businesses in the United States, Latin America, and the Middle East. A longtime techie, Hill cut her teeth in senior business development and operational roles in the software industry. She speaks frequently about small business, regularly appears on MSNBC, serves on the advisory boards of three startup companies, and is a small business board member for the Huffington Post. Dedicated to the advancement of women entrepreneurs, Hill also serves on the advisory boards of Women in Wireless and Astia, which she launched and led in New York.
Cláudia Hirawat, senior vice president, corporate development for PTC, spearheads the company's collaborations, with responsibility for business and corporate development. Joining PTC in 2000 as its seventh employee, Hirawat played a key role in building PTC through direct involvement in fundraising, operational directives, public and investor relations, patient and professional advocacy, and commercial development. Prior to PTC, Hirawat was a vice president at LedbetterStevens, a management consulting and senior-level retained search firm in New York focused exclusively in the biopharmaceutical industry. During her five years at LedbetterStevens, she managed projects for a Pfizer, Pharmacia, Bristol Myers Squibb Co., Celera Genomics, Coelacanth Corp., SpotFire, IBM Consulting/The Wilkerson Group, and The Boston Consulting Group, among others.
Prior to becoming Director of the California Institute for Quantitative Biosciences (QB3) in 2004, Regis Kelly served as executive vice-chancellor at University of California-San Francisco, where he oversaw the UCSF research enterprise and was responsible for construction of the new Mission Bay campus.
Kelly is chairman of the Bay Area Scientific Innovation Consortium and has served on the boards of the Malaysian Biotechnology Industry Advisory Board, the Scleroderma Foundation, and Bridge Pharmaceuticals. He is an advisor to the Thailand Bionanotechnology Institute, Ho Chi Minh City Biotechnology Department Corp., University of Oxford Systems Biology Program, and the San Francisco Mayor's Biotechnology Advisory Group. He joined the UCSF Department of Biochemistry in 1971 and has served as director of the Cell Biology Graduate Program, director of the Hormone Research Institute, and chair of the Department of Biochemistry and Biophysics. He earned an undergraduate degree in physics from the University of Edinburgh and a Ph.D. in biophysics from the California Institute of Technology.
Andrew Mackintosh joined the Royal Society in February 2008 as chief executive of the new Royal Society Enterprise Fund, following a period as chief executive of a biotechnology instrumentation startup. The Enterprise Fund is an early-stage technology investment fund backed by philanthropy. Mackintosh has more than 20 years of commercial and general management experience in high-technology companies, including seven years as CEO of Oxford Instruments plc, a £200m revenue international technology business.
Mackintosh has a Ph.D. in Physics from the University of Cambridge, is a member of the Institute of Directors and a Fellow of the Institute of Physics, and has served on numerous national and regional committees concerned with technical innovation and competitiveness. He speaks fluent French and conversational Japanese.
Allan W. May
Allan May is a founder of Life Science Angels (www.lifescienceangels.com ), the largest angel organization in the United States focused solely on early-stage medical device and life science startups, and comprised solely of high-net-worth individuals from the medical device or biotech fields. Since 2005, LSA has invested more than $40 million in thirty-five early-stage companies, attracted in excess of $700 million in contemporary or follow-on venture capital, and achieved five favorable exits. In 2011, May launched the Life Science Angel Network, a syndicate of angel groups throughout the United States that will focus on increasing the syndication and capitalization of highly vetted health care startups.
In 2007, May joined renowned inventor, entrepreneur, and cardiac surgeon Dr. Thomas Fogarty in co-founding Emergent Medical Partners, a boutique venture fund focused on early-stage medical device company creation and investing. EMP has made twenty-five investments with four successful exits, including eValve and Ardian.
May is chairman of the board of the Kauffman Foundation’s Angel Resource Institute. ARI, a nonprofit devoted to promoting and studying angel investing, works closely with the Angel Capital Association in furthering angel investing and entrepreneurial mentoring. In 2012, ARI released the first Halo Report, which tracks early-stage investment by angel groups.
May has been founder, chairman/CEO, or investor in more than fifty medtech and biotech startups, including Athenagen (Comentis), Nanostim, nSpine, and BioMimedica. He lectures frequently at universities, conferences, and government programs on trends and developments affecting early-stage biotech and medtech investing. He co-chaired Singularity University’s Innovation and Entrepreneurship Track at its 2011 FutureMed Program, and is a member of the editorial board of Elsevier Windhover’s In Vivo magazine.
Sandra Miller is an expert in entrepreneurship education. She has developed and led innovative programs, fellowships, and conferences, focusing primarily on the healthcare sector.
Miller is a consultant to the Fogarty Institute for Innovation, which seeks to energize and accelerate the process of medical device development. She serves on the advisory board of Modular Surgical, an early-stage medical device company in Silicon Valley, and played a major role in the formation and growth of two world-renown entrepreneurship education programs: Kauffman Labs for Enterprise Creation and the Stanford Biodesign Program. For Stanford's Bioengineering Department, Miller also was the founding program director of a pioneering seed grant program. She has advised more than 100 early-stage, technology-based companies and frequently lectures on entrepreneurship education, the commercialization of university research, and related policies.
Miller has served as a Phase II reviewer for the National Science Foundation's SBIR/STTR grants program's biotechnology section and is a past trustee of the Licensing Executives Society Foundation. Prior to receiving an MBA from Pepperdine University, she completed her undergraduate studies at San Jose State University.
Lesa Mitchell, vice president of the Kauffman Foundation’s initiatives focused on advancing innovation, identifies programmatic or policy levers that can accelerate invention and innovation. Under her leadership, the Foundation is defining and codifying alternative commercialization pathways, and identifying new models to foster innovation. Mitchell was instrumental in founding the Kauffman Innovation Network/ iBridge Network, the Translational Medicine Alliance, and the National Academies-based University-Industry Partnership, and is a leader in the replication of innovator-based mentor programs across the United States. In addition, Mitchell serves on the board of the Regenerative Medicine Foundation.
Prior to joining Kauffman, Mitchell spent twenty years in global executive roles at Aventis, Quintiles, and Marion Laboratories, and ran an electronic clinical trials consulting business in support of global pharmaceutical clients.
Alexander Osterwalder is an independent author, speaker, and advisor with a particular focus on business model innovation, strategic management, and management innovation. Focusing on business model innovation, he regularly speaks and conducts workshops in companies, in business schools, and at conferences around the world. His work on business models can be found at http://business-modeldesign.blogspot.com.
Osterwalder also is partner at Arvetica, a consulting boutique focusing on the private banking and wealth management industry. His role includes business development and management of a peer knowledge exchange platform for senior executives in private banking. Previously, Osterwalder founded and ran BusinessModelDesign.com, a consulting boutique active in strategy consulting with a focus on business model innovation. He also helped develop and implement the strategy and business concept of The Constellation, a globally active nonprofit network that brought knowledge management methods from the private sector to the health sector to better respond to the challenges of HIV/AIDS and malaria. Osterwalder, who holds a Ph.D. in management information systems, was an entrepreneur in the banking sector and an online business journalist for BILANZ. He is an inaugural member of the Open World Initiative of the Evian Group at IMD, Switzerland.
Committed to changing the paradigm of cancer care, Kim Popovits is president, CEO and COO of Genomic Health. Prior to joining the company, Popovits served in various leadership roles at Genentech, Inc., a biotechnology company dedicated to using human genetic information to discover, develop, manufacture, and commercialize medicines to treat patients with serious or life-threatening medical conditions. During her fifteen years at Genentech, Popovits led the successful commercialization of fourteen new therapies, including Herceptin®, the revolutionary, targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Before joining Genentech, Popovits was division manager for American Critical Care.
Popovits serves on the board for BayBio, Northern California's life science association, and as president of The Coalition for 21st Century Medicine, whose mission is to improve health care quality by encouraging research, development, and commercialization of innovative diagnostic technologies.
Women Health Care Executives named Popovits Woman of the Year in 2008, and The San Francisco Business Times has included her on its Most Influential Women in the Bay Area list for the past six years. Popovits holds a B.A. in Business from Michigan State University.
Sofie Qiao is president, CEO, and co-founder of LINQ Pharmaceuticals, Inc., a transpacific small molecule drug discovery company. Prior to co-founding LINQ, she served as a business advisor for Hua Medicine and was founder and president of LEAD Therapeutics, a small molecule drug discovery company that adopted a United States/China hybrid business model. Qiao formulated LEAD's business plan, assembled a management team and raised Series A financing of $17 million in 2007. BioMarin acquired the company in February 2010 for up to $97 million.
Before becoming an entrepreneur, Qiao worked at Genzyme Corporation, McKinsey & Company, Syrrx (now Takeda San Diego), and Discovery Partners International (now BioFocus DPI of Galapagos) in a variety of functions. A Beijing native, she received her B.A. in chemistry from Harvard University and her Ph.D. in organic chemistry from MIT.
Avi Roop, CEO of Miret Surgical, has twelve years of medical device industry experience across ten technology initiatives and four commercially available medical devices. As a global marketing manager at St. Jude Medical, he was involved with trans-catheter aortic valve, carotid stent, vascular closure, and vascular access products. Prior to his marketing role, Roop was a St. Jude Medical program manager leading the design and development of an irrigated cardiac ablation catheter and a suture-based vascular closure device.
As an engineer at St. Jude Medical, Vascular Science and Boston Scientific-Scimed, he designed products for percutaneous bypass surgery, interventional electrophysiology, and vascular closure. He holds six U.S. patents, two international patents, and sixteen published U.S. patent applications.
Roop was a 2008–2009 Cottrell Fellow and a 2009–2010 Kauffman Pediatric Medical Device Innovation Fellow. He holds a bachelor’s degree in mechanical engineering from the University of Minnesota.
Tito A. Serafini, PhD, is the CEO and a director of Atreca, Inc., and chief scientific officer of Nuon Therapeutics, Inc. He was a co-founder of Renovis Inc., where he served in multiple roles, including as vice president of discovery research and chief discovery scientist, vice president of technology, head of research, and head of the M&A team. Serafini now is a consultant to the company. Prior to founding Renovis, he served as assistant professor of cell and developmental biology and neurobiology in the Department of Molecular and Cell Biology at the University of California-Berkeley.
Serafini serves a key leadership role in various scientific and corporate endeavors, including enhancing Renovis’s preclinical and clinical pipeline, analyzing new opportunities for its research and development efforts and representing those efforts in corporate development and investor relations, and expanding collaborations with academic centers. He also serves as chairman of the Scientific Advisory Board for Nuon Therapeutics. Serafini, who has won multiple major awards for his basic research achievements, holds a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University, and was a postdoctoral fellow at the University of California-San Francisco.
Jeffrey Schox is a registered patent attorney and the founding member of Schox Patent Group. He is registered to prepare, file, and prosecute patent applications throughout the United States. Drawing on his experience of twelve years in patent law and six years in angel investing, Schox builds patent portfolios that enable startups to increase value and attract funding. With degrees in mechanical and electrical engineering from the University of Michigan, he has filed more than 400 patent applications on a broad range of cutting-edge inventions, including vehicle systems, medical devices, electrical systems, computer software, and clean technologies. Before starting his own law firm, Schox worked at Brinks Hofer Gilson and Lione, one of the nation’s largest patent law firms, where he coordinated the majority of patent applications for a Fortune 100 company.
Risa Stack is a partner at Kleiner Perkins Caufield & Byers, which invests across all stages of new ventures. Since joining the firm in 2003, she has worked to build and support KPCB’s personalized medicine portfolio. In addition to her work with portfolio companies, she is involved in developing therapeutics companies, and in developing public policy in molecular diagnostics and personalized medicine. She has been the founding CEO and a board member of several personalized medicine companies. Stack has fifteen years of experience investing in personalized medicine, therapeutics, and platform technologies. Most recently, she has focused on starting companies, often taking operational roles.
Before joining KPCB, Stack was a principal in the life science practice at J.P. Morgan Partners, where she sponsored a series of domestic and international investments and managed a portfolio of Israeli early-stage life sciences and IT companies.
Stack received her BS degree in genetics and development with distinction from the University of Illinois and her PhD in immunology from the University of Chicago. A member of the second class of Kauffman Fellows, Stack also serves as a member of the advisory board of the National Summit on Personalized Healthcare and in GE’s Healthymagination effort. In 2004, the San Francisco Business Times named her one of the 100 Most Influential Women in Business.
Halle Tecco recognized the need and potential for startups in the digital health space while working at Apple’s App Store covering the health and medical vertical. Today, she is the founder and CEO of RockHealth, the first startup accelerator devoted exclusively to health companies. Previously, she founded Yoga Bear, a national nonprofit that provides yoga to the cancer community in hospitals and at more than 200 partner studios.
Tecco has been named as one of “12 Entrepreneurs Reinventing Healthcare” by CNN and one of “15 Women to Watch in Tech” by Inc. magazine, and was a L’Oreal “Woman of Worth” Honoree. Tecco has written for Harvard Business School Publishing, Stanford Social Innovation Review, Glamour.com and ForbesWoman. She has a BS degree from Case Western Reserve University and an MBA from Harvard Business School.
Troy Wilson, co-founder of Intellikine, serves as the company’s president and CEO. Wilson was formerly co-founder and chief business officer at Ambrx, a biotechnology company focused on optimizing protein-based medicines using non-natural amino acids. He also was a co-founder of Wildcat Discovery Technologies, and previously served as vice president, business development and general counsel at the Genomics Institute of the Novartis Research Foundation (GN